306 results about "Citrulline" patented technology

A sensor is disclosed, for implantation within a blood vessel to monitor a substance in or property of blood. In one embodiment, the sensor detects nitric oxide or a nitric oxide metabolite. In another embodiment, other substances such as glutamate, aspartate, arginine, citrulline, acetylcholine, calcium, potassium, or dopamine are monitored. The sensor may be attached to a support structure such as a stent, guidewire, or catheter. In a further embodiment, a catheter is disclosed that extracts patient fluid to a sensor outside the body for monitoring a substance or property of the patient fluid. Methods are also disclosed.

Polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or alanine; A5 is a residue of tyrosine, phenylalanine, alanine, naphthylalanine, or citrulline; A7 is a lysine or arginine residue whose carboxyl group may be converted into amido; and X is a residue of D-ornithyl-proline, prolyl-D-ornithine, D-lysylproline, or the like, with the proviso that any one of A1, A3, A4, A5, A6 and A7 is a residue of alanine or the like or that X is citrulline or the like).

The invention discloses a metabolism marker for screening and monitoring a colorectal cancer. The metabolism marker is beta-hydroxybutyrate, 5-hydroxytryptamine, lysophosphatidyl choline (C14:0), lysophosphatidyl choline (C16:1), alpha-ketobutyrate, fumaric acid, aspartic acid, 2-octene diacid, glycerin, glyceric acid, tryptophan, aconitate, citric acid, ornithine, glycerol monopalmitate, creatinine, methionine and citrulline. The invention also provides a kit with auxiliary functions of early diagnosis and prognosis monitoring on the colorectal cancer. The application of the micromolecule metabolism marker to monitoring of the colorectal cancer not only greatly improves the accuracy, but also has great guiding significance for development of a subsequent clinical application study.

A medical composition for treating sexual disfunction, impotence, immunodeficiency, chronic fatigue, and hepal and renal disfunction is prepared from ornithin and citrulline or their salts, jujube, ginkgo seed and ginseng. Its advantages are high curative effect and no toxic by-effect.

The present invention provides novel polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or alanine; A5 is a residue of tyrosine, phenylalanine, alanine, naphthylalanine, or citrulline; A7 is a lysine or arginine residue whose carboxyl group may be converted into amido; and X is a residue of D-ornithyl-proline, prolyl-D-ornithine, D-lysylproline, or the like, with the proviso that any one of A1, A3, A4, A5, A6 and A7 is a residue of alanine or the like or that X is citrulline or the like), and methods of using same in the treatment of HIV.

The present invention relates to an arginine deiminase mutant with partial lysine-deficient and preparation and application thereof. The arginine deiminase mutant of the present invention has enzymatic activity of degrading arginine into citruline; compared with the arginine deiminase with the amino acid sequence of SEQ ID NO: 1, the amino acid sequence comprises one or more of K9N, T, K59Q, K66R, A, K93E, A, Q, K111R, A, K119Q, L, M, K121Q, I, K122E, L, K126E, S, R, K178I, E, D, K196I, R, K209G, T, D, K243E, V, R, K249D, Q, K263N, Q, K279Y, T, K293R, H, E, K325V, I, K380T, R, E, and K406E, D, S substitutions. Compared with PEG modified natural derived arginine deiminase, the PEG modified arginine deiminase mutant of the present invention retain better bioactivity; and because the quantity of lysine in arginine deiminase is reduced, the PEG modified products are more uniform and can be applied to clinical treatment of hepatoma, melanoma and the like.

A composition comprising an amphoteric or pseudo-amphoteric agent and a polyhydroxy alpha hydroxyacid existing as a free acid, lactone, or salt, and isomeric or non-isomeric forms thereof is provided. The amphoteric or pseudo-amphoteric agent can be selected from amino acids, dipeptides, aminoaldonic acid, aminouronic acid, lauryl aminoproplyglycine, aminoaldaric acid, neuraminic acid desulfated heparin, deacetylated hyaluronic acid, hyalobiuronic acid, chondrosine, deacetylated chondroitin, creatine, creatinine, hydroxyproline, homocysteine, homocystine, homoserine, ornithine, citrulline, phosphatidylserine, and sphingomyelin. The composition may contain other additives, including cosmetic or pharmaceutical agents for topical treatment of dermatological disorders.

The invention relates to the field of biological medicine, and in particular relates to liver targeted medicine. The medicine is chemical micromolecular medicine connecting galactosamine. The chemicalmicromolecular medicine is medicine for treating liver diseases or liver-related diseases. The chemical micromolecular medicine is prepared from but not limited to thyroxine T3, sorafenib, taxol, regorafenib, lamivudine, entecavir, telbivudine, statins, fibrates, niacin, bile acid sequestrants, other hepatitis virus DNA (RNA) polymerase inhibition compounds and the like. The galactosamine is tervalent acetylgalactosamine. The connection is the direct connection of the galactosamine and the chemical micromolecular medicine or the connection through linking fragments; the linking fragments comprise but not limited to carbon chains, disulfide bonds, pyrophosphate diester, cysteic acid, polypeptide and thioether or valine-citrulline. The medicine provided by the invention has the advantages that the liver targeted performance is improved; the medicine curative effect is enhanced; the toxic and side reactions on other non-targeted tissues are few.

The invention discloses a cyclic chimeric citrullinated peptide antigen and an application thereof. The preparation of the cyclic chimeric citrullinated peptide antigen comprises the following steps: firstly connecting and jogging three small-molecular antigen peptides, namely a citrullinated peptide1, a citrullinated peptide 2 and a citrullinated peptide 3 derived from a silk polymerizing protein/an intermediate filament protein, and then synthetizing a cyclic polypeptide with a similar protein beta-corner structure by forming a disulfide bond through two cysteines inserted into the end N and the end C of a chimeric peptide. The cyclic chimeric citrullinated peptide antigen coats a solid-phase vector to prepare an indirect enzyme linked immunosorbent assay kit used for detecting the hypotype of multiple anti-citrullinated protein antibodies contained in RA (Rheumatoid Arthritis) serum. The cyclic chimeric citrullinated peptide antigen and the ELISA kit thereof which are disclosed by the invention have the advantages of simple preparation and experimental operation process, good result repeatability, qualification or quantification and wide clinical application and scientific research value and are outstandingly enhanced in detection sensibility and diagnosis value on RA compared with an international similar kit.

The invention discloses a chlorella silk mask for eliminating the turbid, beautifying skin and repairing radiation damage. The mask is manufactured by soaking non-woven fabric in mask essence. The mask essence comprises, by weight, 50-80 parts of water, 2-10 parts of 1,3-butanediol, 5-10 parts of chlorella extracts, 5-10 parts of rose extracts, 1-5 parts of betaine, 1-5 parts of 1,2-propylene glycol, 0.5-2 parts of acetyl hexapeptide-1, 0.25-0.5 part of xanthan gum, 0.2-1 part of acetyl tetrapeptide-2, 0.3-0.5 part of sodium hyaluronate, 0.8-1.5 parts of serine, 0.8-1.5 parts of citrulline, 0.5-1 part of nicotinamide, 0.5-1 part of methylisothiazolinone, 0.1-0.5 part of PEG-40 hydrogenated castor oil and 0.005-0.01 part of essence. The mask can deeply purify pores, clean away abundant grease, and promote water and grease balance of the skin, enables the skin cool, comfortable and vigorous and meanwhile has an anti-radiation function.

The invention relates to a method for purifying citrulline from a watermelon, which comprises the following steps: removing the pulp of a citrulline, carrying out ultrasonic extraction twice to three times with acid water, settling impurities with a settling agent, purifying citrulline with macroporous resin columns and strong-acid cation resin columns in series, eluting with ammonia water, carrying out concentrative crystallization, dissolving roughly crystallized substances with acid water, adjusting the pH with ammonia water, recrystallizing and the like. The method has the advantages of high extraction efficiency, low energy consumption and high product purity.

The invention discloses five categories of denaturizing allosteric cyclic citrulline polypeptide, fusion protein, antibodies and a kit thereof, which are formed by synthesizing related antigens that antibodies of rheumatoid arthritis patients can specifically recognize, independent designing amino acid sequences and structures with special derivations, and tests prove that the invention can combine with antibodies in RA blood serum and have better immunity reaction compared with the existing cyclic citrulline polypeptide detections, such as CCP and the like. The polypeptides carry out denaturizing and allosteric design and synthesis according to metabolism of arginine residues, and compared with projects of CCP, C-CRP and RF and the like, the five categories of denaturizing allosteric cyclic citrulline polypeptides are characterized by good specificity, high relevance ratio and high primitive diagnosis rate, etc.

A prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria which may occur in humans or animals upon loading of exercise or stress or the like is provided.

According to the present invention, the prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria which comprises a branched-chain amino acid such as valine, leucine or isoleucine or a salt thereof, a basic amino acid such as ornithine, arginine, lysine, histidine or citrulline or a salt thereof and glutamine or a salt thereof as active ingredients can be provided.

The invention discloses a kit for determining an anti-cyclic citrullinated peptide (Anti-CCP) antibody. The kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises a buffer solution, inorganic salt, surfactant, preservative, interference removing protein, modified CCP-sensitized nano poly styrene (PS) microspheres and ultrapure water; the reagent R2 comprises a buffer solution, inorganic salt, surfactant, preservative, an anti Anti-CCP second antibody and ultrapure water; and the weight ratio of the reagent R1 to the reagent R2 is (50-90):(10-50). According to the method, the Anti-CCP is determined by adding the anti Anti-CCP second antibody by a latex booster immunization transmission turbidimetry, a detection signal is subjected to two-stage amplification, the detection sensitivity is improved, and the determination range is enlarged; and the kit can be applied to an automatic biochemical analyzer to shorten detection time, and improve detection efficiency.

Compositions and methods for managing inflammation in the elderly by delivering a selection of amino acids, including arginine and/or citrulline, in a synergistic ratio with omega-3 fatty acids and carbohydrates with a low glycemic index.

The invention discloses a solid-phase synthesis method of cetrorelix. The method completely avoids toxic [D-Cit(Ac)]-cetrorelix impurities of D-citrulline side chain acetylation. According to the method, amino resin is used as an initial resin carrier, corresponding Fmoc-amino acids in a cetrorelix sequence are sequentially connected with the solid-phase synthesis method, and all-protected cetrorelix peptide resin is obtained through a condensation reaction and a deprotection reaction; then acidolysis cutting and sedimentation by the aid of diethyl ether are performed, and crude cetrorelix peptides are obtained; cetrorelix acetate is obtained through chromatographic purification, acetate conversion and freeze-drying. According to the method, Ac-D-2Nal-OH is selected as connection of the last amino acid, so that acetylation termination is avoided. Both a solid-phase synthesis technology and a liquid-phase synthesis technology can be adopted, few technological byproducts are produced, and separation and purification are easy. The purity of the finally obtained cetrorelix acetate product is up to 99%, the yield is up to 40%, and the method has the considerable economical application value and the broad application prospect.

The invention relates to a method for extracting compound amino acid from watermelons or seeding watermelons, which belongs to the technical field of natural product extraction in the food and medicine industry. The invention uses watermelons or seeding watermelons as raw materials and comprises the steps: firstly, watermelon peel and watermelon pulp are separated and are respectively extracted for juice; the obtained juice is mixed, micro filtered and ultrafilter to remove insoluble substances and large molecular substances,; reverse osmosis and nanofiltration are carried out to the juice; after the ph value of the permeate liquid is adjusted, macroporous and strong acidic cation exchange resin columns are added in the permeate liquid; isocratic elution is carried out by using ammonia as an eluant; the eluant is distilled by pressure reduction for deaminase and decoloration; a concentrated solution is dried by a high-speed centrifugal spraying drier to obtain compound amino acid which is rich in amino acid up to over 20 types, such as citrulline, gamma-aminobutyric acid, and the like. The obtained product is a pure natural product, does not contain harmful substances, has good purity quality and can be directly used as food additives and raw materials of health food or medicine.

The invention discloses a method for extracting citrulline from selenium-contained watermelon plant tissues. Citrulline, and partial glutamic acid and arginine are separated out through the steps of juicing, enzyme treatment clarification, concentration, anion exchange resin adsorption, ammonia water elution, crystallization and recrystallization. The yield of the citrulline product is 0.3%; the product is high in purity and low in energy consumption. The method provided by the invention has the advantages that resin washing water, ammonia water and the like are recycled, the process is low in pollution on environment and comprehensive utilization of watermelons and tissues thereof is realized.

The invention discloses a test method of liquid spectrum finger diagram of melon, or melon injection, comprising that (1), preparing melon, or melon injection into a sample solution, (2), respectively absorbing citrulline water solution and the sample solution, to be filled into a liquid spectrometer, and using the solution of phthalaldehyde and the solution of chloride aminic acid fluorenes methyl ester to process derivatization, (3), testing liquid spetrum. The inventive test method first discloses a liquid spectrum finger diagram of melon or melon injection, with high accuracy, stability and repeatability, as one analysis test method which can control the product quality, used in product quality test. The inventive method first obtains the high-effect liquid spectrum contrast finger diagram of melon and melon injection, as diagram 1 and diagram 2.

The invention disclosed herein demonstrates that that the adaptive process in the intestine can be tracked using plasma citrulline. It further demonstrates that plasma citrulline is of clinical utility as a biomarker for improvements in intestinal function.

The present invention provides a feed for a farmed fish, which contains an animal raw material, a part or the whole of which has been substituted with a plant raw material, and/or a plant raw material as a protein source, and can prevent a decrease in growth efficiency and feed efficiency for fishes, a method for promoting the growth of a farmed fish using the feed for a farmed fish, and an additive for a feed for preparing the feed for a farmed fish. The present invention relates to a feed for a farmed fish, which contains an animal raw material, a part or the whole of which has been substituted with a plant raw material, and/or a plant raw material as a protein source, and is characterized by containing at least one amino acid selected from the group consisting of alanine, glutamic acid, glutamine, proline, ornithine, citrulline, and arginine.

The invention relates to a functional peptide-reinforced healthcare food which comprises, by weight, 2 to 5 parts of glutathione preparation material, 2 to 5 parts of sea cucumber or marine fish protein peptide preparation material, 0.04 to 0.1 part of R-lipoic acid, (1 to 3)X10-5 parts of folic acid, 0.2 to 0.5 part of procyanidins, 2 to 5 parts of food grade L-citrulline and 4 to 8 parts of excipient or filler. The invention provides a glutathione high-yield bacterial strain saccharomyces cerevisiae which can reduce production cost of glutathione and enables glutathione to be more widely applied nutriment. Glutathione serves as an important raw material, and a small molecular weight peptide with an important physiological function, citrulline and other physiological active materials with synergistic effect are matched with glutathione so as to provide the healthcare food which has the functions of enhanced antioxidation, aging resistance and cardiovascular protection.